A range of behaviors presumed to be related to dopaminergic medications have been recently
recognized in Parkinson's disease (PD). We evaluated 50 consecutive cognitively intact …

BACKGROUND AND PURPOSE: Quantitative evaluation of midbrain atrophy may be useful
in differentiating progressive supranulear palsy (PSP) from Parkinson disease (PD); …

Background Pathological gambling (PG) may develop in patients with Parkinson disease (PD)
during dopamine replacement therapy, but the underlying neural correlates are still …

We assessed the effect of 3‐month treatment of sertraline (50 mg) or low‐dose amitriptyline (25
mg) on depression and quality of life in 31 patients with Parkinson's disease in a …

Objective To evaluate the prevalence of psychosis associated with Parkinson's disease (PSY-PD)
in its early stages, its incidence over a 24 month follow-up period and the association …

We analysed the Leucine-Rich Repeat Kinase 2 (LRRK2) gene for the G2019S mutation in
1245 consecutive, unrelated patients with primary degenerative parkinsonism, and collected …

Objective Dopamine dysregulation syndrome (DDS) refers to a compulsive pattern of
dopaminergic drug misuse complicating Parkinson's disease (PD). To date, few data are available …

We prospectively evaluated 20 patients with Parkinson's disease (PD) preoperatively and
12 months after subthalamic nucleus-deep brain stimulation (STN-DBS). All patients had …

The cognitive status of patients with Parkinson’s disease (PD) who developed pathological
gambling (PG) during dopamine replacement therapy has been poorly explored. We …

The frequency of psychopathological symptoms in patients with Parkinson’s disease (PD) is
often underestimated because of the lack of comprehensive evaluation tools. A total of 486 …